SEHK:1801Biotechs
Assessing Innovent Biologics (SEHK:1801) Valuation After New IBI3055 Autoimmune Preclinical Data
Innovent Biologics (SEHK:1801) shares moved in response to fresh product news after the company presented initial preclinical data for IBI3055, a tri specific anti CD19/BCMA/CD3 T cell engager for autoimmune diseases, in Boston.
See our latest analysis for Innovent Biologics.
The latest IBI3055 update lands after a mixed but generally positive stretch for investors, with a 30 day share price return of 9.46%, year to date share price return of 12.31%, and a 1 year total shareholder return of...